Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Lnp023
2. 1644670-37-0
3. Lnp-023
4. Iptacopan [inn]
5. Iptacopan [usan]
6. Nvp-lnp023-nx
7. Nvp-lnp023
8. 8e05t07z6w
9. 4-[(2s,4s)-4-ethoxy-1-[(5-methoxy-7-methyl-1h-indol-4-yl)methyl]piperidin-2-yl]benzoic Acid
10. 4-[(2~{s},4~{s})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{h}-indol-4-yl)methyl]piperidin-2-yl]benzoic Acid
11. Benzoic Acid, 4-((2s,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)-2-piperidinyl)-
12. Benzoic Acid, 4-[(2s,4s)-4-ethoxy-1-[(5-methoxy-7-methyl-1h-indol-4-yl)methyl]-2-piperidinyl]-
13. Iptacopan [who-dd]
14. Unii-8e05t07z6w
15. Chembl4594448
16. Schembl16400416
17. Gtpl10710
18. Us9682968, Example-26a
19. Bdbm160475
20. Ex-a5728
21. Who 11259
22. Zinc223246892
23. At30389
24. Compound 41 [pmid: 32073845]
25. Hy-127105
26. Cs-0093107
27. A935227
28. 4-((2s,4s)-(4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid
29. 4-((2s,4s)-4-ethoxy-1-((5-methoxy-7-methyl-1h-indol-4-yl)methyl)piperidin-2-yl)benzoicacid
30. Jgq
Molecular Weight | 422.5 g/mol |
---|---|
Molecular Formula | C25H30N2O4 |
XLogP3 | 1.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 7 |
Exact Mass | 422.22055744 g/mol |
Monoisotopic Mass | 422.22055744 g/mol |
Topological Polar Surface Area | 74.8 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 594 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
NDC Package Code : 44139-0100
Start Marketing Date : 2023-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: Fabhalta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Fabhalta Sustains Positive Phase 3 Results in C3 Glomerulopathy
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2024
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is approved for the treatment of patients with IgA nephropathy (IgAN).
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: Fabhalta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Receives FDA Approval for Fabhalta, A Complement Inhibitor for IgAN
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is approved for the treatment of patients with IgA nephropathy (IgAN).
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2024
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: Fabhalta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Data Show Significant Proteinuria Reduction of 38.3% for IgA Nephropathy Patients
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients with IgA nephropathy (IgAN).
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: Fabhalta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis' Fabhalta® (iptacopan) Gets Positive CHMP Opinion for PNH
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia.
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2024
Details:
LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinuria reduction.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway being developed in Phase 3 for patients with C3 glomerulopathy, which met its primary endpoint by providing clinically meaningful and statistically significant proteinu...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Details:
FDA approved Fabhalta® (iptacopan), a Factor B inhibitor of the alternative complement pathway 15-17, as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: Fabhalta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis receives FDA Approval for Fabhalta® (iptacopan), offering Superior Hemoglobin Improvemen...
Details : FDA approved Fabhalta® (iptacopan), a Factor B inhibitor of the alternative complement pathway 15-17, as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Brand Name : Fabhalta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 02, 2023
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2023
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Details:
LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysis in PNH.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: LNP023
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LNP023 (iptacopan) is an investigational first-in-class, orally administered targeted factor B inhibitor of the alternative complement pathway. It acts upstream of the C5 terminal pathway, preventing not only intravascular but also extravascular hemolysi...
Brand Name : LNP023
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Regulatory Info : RX
Registration Country : USA
Brand Name : FABHALTA
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 200MG BASE
Packaging :
Approval Date : 2023-12-05
Application Number : 218276
Regulatory Info : RX
Registration Country : USA
RLD : Yes
TE Code :
Brand Name : FABHALTA
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 200MG BASE
Approval Date : 2023-12-05
Application Number : 218276
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
https://www.pharmacompass.com/radio-compass-blog/fda-approvals-slump-19-in-h1-2024-nash-copd-pah-get-new-treatment-options
Patents & EXCLUSIVITIES
Exclusivity Code : NCE
Exclusivity Expiration Date : 2028-12-05
Application Number : 218276
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-456
Exclusivity Expiration Date : 2030-12-05
Application Number : 218276
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-949
Exclusivity Expiration Date : 2027-08-07
Application Number : 218276
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
A Iptacopan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Iptacopan, including repackagers and relabelers. The FDA regulates Iptacopan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Iptacopan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Iptacopan supplier is an individual or a company that provides Iptacopan active pharmaceutical ingredient (API) or Iptacopan finished formulations upon request. The Iptacopan suppliers may include Iptacopan API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Iptacopan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Iptacopan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Iptacopan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Iptacopan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Iptacopan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Iptacopan suppliers with NDC on PharmaCompass.
Iptacopan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Iptacopan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Iptacopan GMP manufacturer or Iptacopan GMP API supplier for your needs.
A Iptacopan CoA (Certificate of Analysis) is a formal document that attests to Iptacopan's compliance with Iptacopan specifications and serves as a tool for batch-level quality control.
Iptacopan CoA mostly includes findings from lab analyses of a specific batch. For each Iptacopan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Iptacopan may be tested according to a variety of international standards, such as European Pharmacopoeia (Iptacopan EP), Iptacopan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Iptacopan USP).
LOOKING FOR A SUPPLIER?